1. R Doglia (2017). The need of dermatologists, psychiatrists and psychologists joint care in psychodermatology. An Bras Dermatol, 92(1), 63-67.
2. K Paucar (2018). Relación bidireccional de las patologías cutáneas con los trastornos mentales. Rev Cient Cienc Méd, 21(1), 84-89.
3. Katlein Franca,Anna Chacon,Jennifer Ledon,Jessica Savas,Keyvan Nouri (2013). Pyschodermatology: a trip through history. Anais Brasileiros de Dermatologia, 88(5), 842-843.
4. S Yadav,T Narang,M Kumaran (2013). Psychodermatology: A comprehensive review. Indian J Dermatol, Venereol Leprol, 79, 176-192.
5. Bruce Mcewen (2012). Brain on stress: How the social environment gets under the skin. Proceedings of the National Academy of Sciences, 109(supplement_2), 17180-17185.
6. Petra Arck,Andrzej Slominski,Theoharis Theoharides,Eva Peters,Ralf Paus (2006). Neuroimmunology of Stress: Skin Takes Center Stage. Journal of Investigative Dermatology, 126(8), 1697-1704.
7. Ying Chen,John Lyga (2014). Brain-Skin Connection: Stress, Inflammation and Skin Aging. Inflammation & Allergy-Drug Targets, 13(3), 177-190.
8. J Escalas,A Guerra,M Rodríguez-Cerdeira (2010). Tratamiento con psicofármacos de los trastornos psicodermatológicos. Actas Dermo-Sifiliográficas, 101(6), 485-494.
9. Jan-Marino Ramirez (2014). The Integrative Role of the Sigh in Psychology, Physiology, Pathology, and Neurobiology. Progress in Brain Research, 209, 91-129.
10. K Sayar,O Köse,S Ebrinç,M Şetin (2001). Hopelessness, Depression and Alexithymia in Young Turkish Soldiers Suffering from Alopecia areata. Dermatology and Psychosomatics / Dermatologie und Psychosomatik, 2(1), 12-15.
11. H Richards,D G Fortune,C Griffiths,C Main (2005). Alexithymia in patients with psoriasis: clinical correlates and psychometric properties of the Toronto Alexithymia Scale-20. J Psychosom Res, 58, 89-96.
12. G Maniaci,M Epifanio,M Marino,S Amoroso (2006). The presence of alexithymia investigated by the TAS-20 in chronic urticaria patients: A preliminary report. Allerg Immunol, 38, 15-19.
13. A Picardi,P Pasquini,M Cattaruzza,P Gaetano,C Melchi,G Baliva (2003). Stressfull life events, social support, attachment security and alexithymia in vitíligo. A case-control study. Psychother Psychosom, 72, 150-158.
14. Amanda Mosini,Marcelo Saad,Camilla Braghetta,Roberta Medeiros,Mario Peres,Frederico Leão (2019). Neurophysiological, cognitive-behavioral and neurochemical effects in practitioners of transcendental meditation - A literature review. Revista da Associação Médica Brasileira, 65(5), 706-713.
15. Madhulika Gupta,Aditya Gupta,Charles Ellis,Caroline Koblenzer (2005). Psychiatric Evaluation of the Dermatology Patient. Dermatologic Clinics, 23(4), 591-599.
16. A Lavda,T L Webb,A Thompson (2012). A meta-analysis of the effectiveness of psychological interventions for adults with skin conditions. British Journal of Dermatology, 167(5), 970-979.
17. Philip Shenefelt (2010). Psychological interventions in the management of common skin conditions. Psychology Research and Behavior Management, 3, 51.
18. Richard Fried (2013). Nonpharmacologic Management of Psychodermatologic Conditions. Seminars in Cutaneous Medicine and Surgery, 32(2), 119-125.
19. Philip Shenefelt (2000). Hypnosis in Dermatology. Archives of Dermatology, 136(3), 393-399.
20. Liana Schreiber,Brian Odlaug,Jon Grant (2011). Diagnosis and treatment of trichotillomania. Neuropsychiatry, 1(2), 123-132.
21. Tiffany Field,Michael Peck,Scott Krugman,Tammy Tuchel,Saul Schanberg,Cynthia Kuhn,Iris Burman (1998). Burn Injuries Benefit from Massage Therapy. Journal of Burn Care & Rehabilitation, 19(3), 241-244.
22. Giovanni Fava,Fiammetta Cosci,Nicoletta Sonino (2017). Current Psychosomatic Practice. Psychotherapy and Psychosomatics, 86(1), 13-30.
23. Heike Gerger,Michaela Hlavica,Jens Gaab,Thomas Munder,Jürgen Barth (2015). Does It Matter Who Provides Psychological Interventions for Medically Unexplained Symptoms? A Meta-Analysis. Psychotherapy and Psychosomatics, 84(4), 217-226.
24. Allan Abbass,Stephen Kisely,Kurt Kroenke (2009). Short-Term Psychodynamic Psychotherapy for Somatic Disorders. Psychotherapy and Psychosomatics, 78(5), 265-274.
25. Mechthild Hartmann,Eva Bäzner,Beate Wild,Ivan Eisler,Wolfgang Herzog (2010). Effects of Interventions Involving the Family in the Treatment of Adult Patients with Chronic Physical Diseases: A Meta-Analysis. Psychotherapy and Psychosomatics, 79(3), 136-148.
26. Giovanni Fava,Jenny Guidi,Chiara Rafanelli,Nicoletta Sonino (2015). The Clinical Inadequacy of Evidence-Based Medicine and the Need for a Conceptual Framework Based on Clinical Judgment. Psychotherapy and Psychosomatics, 84(1), 1-3.
27. Cody Connor (2017). Management of the psychological comorbidities of dermatological conditions: practitioners' guidelines. Clinical, Cosmetic and Investigational Dermatology, Volume 10, 117-132.
28. Sheng-Min Wang,Jung-Bum Kim,Jeong Sakong,Ho-Suk Suh,Kang Oh,Jong-Min Woo,Sang-Woo Yoo,Sang Lee,Sang-Yeol Lee,Se-Won Lim,Seong Cho,Ik-Seung Chee,Jeong-Ho Chae,Jin Hong,Kyoung-Uk Lee (2016). The Efficacy and Safety of Clonazepam in Patients with Anxiety Disorder Taking Newer Antidepressants: A Multicenter Naturalistic Study. Clinical Psychopharmacology and Neuroscience, 14(2), 177-183.
29. M Kavan,G Elsasser,E Barone (2009). Multiple Somatic Complaints (Generalized Anxiety Disorder). Essential Family Medicine, 79, 655-667.
30. Robert Bielski,Anjana Bose,Chung-Chi Chang (2005). A Double-Blind Comparison of Escitalopram and Paroxetine in the Long-Term Treatment of Generalized Anxiety Disorder. Annals of Clinical Psychiatry, 17(2), 65-69.
31. Jonathan Davidson,Anjana Bose,Andrew Korotzer,Hongjie Zheng (2004). Escitalopram in the treatment of generalized anxiety disorder: Double-blind, placebo controlled, flexible-dose study. Depression and Anxiety, 19(4), 234-240.
32. Jonathan Davidson,Anjana Bose,Qin Wang (2005). Safety and Efficacy of Escitalopram in the Long-Term Treatment of Generalized Anxiety Disorder. The Journal of Clinical Psychiatry, 66(11), 1441-1446.
33. Stefan Leucht,Werner Steimer,Stefan Kreuz,Dorothee Abraham,Paul Orsulak,Werner Kissling (2001). Doxepin Plasma Concentrations: Is There Really a Therapeutic Range?. Journal of Clinical Psychopharmacology, 21(4), 432-439.
34. Ajeet Singh,Chad Bousman,Chee Ng,Keith Byron,Michael Berk (2013). Psychomotor depressive symptoms may differentially respond to venlafaxine. International Clinical Psychopharmacology, 28(3), 121-126.
35. Thomas Baghai,Daniela Eser,Hans-Jürgen Möller (2008). Effects of different antidepressant treatments on the core of depression. Dialogues in Clinical Neuroscience, 10(3), 309-320.
36. Andrea Cipriani,Toshiaki Furukawa,Georgia Salanti,John Geddes,Julian Higgins,Rachel Churchill,Norio Watanabe,Atsuo Nakagawa,Ichiro Omori,Hugh Mcguire,Michele Tansella,Corrado Barbui (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. The Lancet, 373(9665), 746-758.
37. Levin,C Gieler,U (2013). Delusions of parasitosis. Semin Cutan Med Surg, 32(2), 73-77.
38. Viraat Patel,John Koo (2015). Delusions of parasitosis; suggested dialogue between dermatologist and patient. Journal of Dermatological Treatment, 26(5), 456-460.
39. J Koo,A Lebwohl (2001). Psychodermatology: the mind and skin connection. Am Fam Phys, 64(11), 1873-1878.
40. S Flann,J Shotbolt,B Kessel,D Vekaria,R Taylor,A Bewley,A Pembroke (2010). Three cases of delusional parasitosis caused by dopamine agonists. Clinical and Experimental Dermatology, 35(7), 740-742.
41. M Kölle,P Lepping,J Kassubek,C Schönfeldt-Lecuona,R Freudenmann (2010). Delusional Infestation Induced by Piribedil Add-On in Parkinson's Disease. Pharmacopsychiatry, 43(06), 240-242.
42. C L Marshall,V Williams,C Ellis,R E Taylor,A Bewley (2017). Delusional infestation may be caused by recreational drug usage in some patients, but they may not disclose their habit. Clin Exp Dermatol, 42(1), 41-45.
43. Cynthia Lorenzo,John Koo (2004). Pimozide in Dermatologic Practice. American Journal of Clinical Dermatology, 5(5), 339-349.
44. Roland Freudenmann,Peter Lepping (2008). Second-Generation Antipsychotics in Primary and Secondary Delusional Parasitosis. Journal of Clinical Psychopharmacology, 28(5), 500-508.
45. Markus Huber,Peter Lepping,Roger Pycha,Martin Karner,Josef Schwitzer,Roland Freudenmann (2011). Delusional infestation: treatment outcome with antipsychotics in 17 consecutive patients (using standardized reporting criteria). General Hospital Psychiatry, 33(6), 604-611.
46. Wei-Lieh Huang,Li-Ren Chang (2013). Aripiprazole in the Treatment of Delusional Parasitosis With Ocular and Dermatologic Presentations. Journal of Clinical Psychopharmacology, 33(2), 272-273.
47. B Ladizinski,K Busse,T Bhutani,J Koo (2010). Aripiprazole as a viable alternative for treating delusions of parasitosis. J Drugs Dermatol, 9(12), 1531-1532.
48. Maarten Bak,Annemarie Fransen,Jouke Janssen,Jim Van Os,Marjan Drukker (2014). Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis. PLoS ONE, 9(4), e94112.
49. Nir Barak,Yaffa Beck,Joseph Albeck (2016). A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Betahistine to Counteract Olanzapine-Associated Weight Gain. Journal of Clinical Psychopharmacology, 36(3), 253-256.
50. Nir Barak,Yaffa Beck,Joseph Albeck (2016). Betahistine decreases olanzapine-induced weight gain and somnolence in humans. Journal of Psychopharmacology, 30(3), 237-241.
51. Jiamei Lian,Xu-Feng Huang,Nagesh Pai,Chao Deng (2016). Ameliorating antipsychotic-induced weight gain by betahistine: Mechanisms and clinical implications. Pharmacological Research, 106, 51-63.
52. S Wong,A Bewley (2011). Patients with delusional infestation (delusional parasitosis) often require prolonged treatment as recurrence of symptoms after cessation of treatment is common: an observational study. British Journal of Dermatology, 165(4), 893-896.
53. Vlasios Brakoulias (2015). Managing obsessive compulsive disorder. Australian Prescriber, 38(4), 121-123.
54. L Ost,E Riise,G Wergeland,B Hansen,G Kvale (2016). Cognitive behavioral and pharmacological treatments of OCD in children: a systematic review and meta-analysis. J Anxiety Disord, 43, 58-69.
55. Bethany Wootton (2016). Remote cognitive–behavior therapy for obsessive–compulsive symptoms: A meta-analysis. Clinical Psychology Review, 43, 103-113.
56. J Goulding (2015). <i>N</i> -acetylcysteine in trichotillomania: further thoughts. British Journal of Dermatology, 172(6), 1683-1684.
57. Jon Grant,Brian Odlaug,Suck Won Kim (2009). N-Acetylcysteine, a Glutamate Modulator, in the Treatment of Trichotillomania. Archives of General Psychiatry, 66(7), 756.
58. D Özcan,D Seçkin (2016). N‐Acetylcysteine in the treatment of trichotillomania: remarkable results in two patients. Journal of the European Academy of Dermatology and Venereology, 30(9), 1606-1608.
59. M Taylor,K Bhagwandas (2014). <i>N</i> ‐acetylcysteine in trichotillomania: a panacea for compulsive skin disorders?. British Journal of Dermatology, 171(5), 1253-1255.
60. Rachel Rothbart,Taryn Amos,Nandi Siegfried,Jonathan Ipser,Naomi Fineberg,Samuel Chamberlain,Dan Stein (2013). Pharmacotherapy for trichotillomania. Cochrane Database of Systematic Reviews, 11, 7662.
61. Daniel Ring (2010). Inexpensive Solution for Habit-Tic Deformity. Archives of Dermatology, 146(11), 1222.
62. C Bowen,J Bidinger,C Hivnor,A Hoover,J Henning (2014). Allergic contact dermatitis to 2-octyl cyanoacrylate. Cutis, 94(4), 183-186.
63. Mark Davis,Michael Stuart (2016). Severe Allergic Contact Dermatitis to Dermabond Prineo, a Topical Skin Adhesive of 2-Octyl Cyanoacrylate Increasingly Used in Surgeries to Close Wounds. Dermatitis®, 27(2), 75-76.
64. Sébastien Lefèvre,Aude Valois,François Truchetet (2016). Allergic contact dermatitis caused by Dermabond<sup>®</sup>. Contact Dermatitis, 75(4), 240-241.
65. Chai Lee,Robert Accordino,Josephine Howard,John Koo (2008). Psychopharmacology in dermatology. Dermatologic Therapy, 21(1), 69-82.
